Document is current

Article History

Received: 18 September 2024

Accepted: 8 November 2024

First Online: 28 November 2024

Declarations

:

: Francesco Pepe has a relevant relationship (advisory fees, honoraria, travel accommodation and expenses, grants, and non-financial support) with Menarini and Roche that is unrelated to the current work. Luisella Righi reports personal fees (for speaker’s bureaus or acting as an advisor) from Roche, MSD, Boehringer Ingelheim, Eli Lilly, BMS, AstraZeneca, Amgen, and Bayer that are unrelated to the current work. Giancarlo Troncone reports personal fees (for speaker’s bureaus or acting as an advisor) from Roche, MSD, Pfizer, Boehringer Ingelheim, Eli Lilly, BMS, GSK, Menarini, AstraZeneca, Amgen, and Bayer that are unrelated to the current work. Umberto Malapelle has received personal fees (for acting as a consultant and/or speaker’s bureaus) from Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientific, Eli Lilly, Diaceutics, GSK, Merck, AstraZeneca, Janssen, Diatech, Novartis, and Hedera that are unrelated to the current work. Umberto Malapelle is an editorial board member of Oncology and Therapy. Umberto Malapelle was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. All other named authors confirm that they have no conflicts of interest to declare.

: Written informed consent was acquired from all patients involved in the study and documented in accordance with the general authorization for processing personal data for scientific research purposes from the Italian Data Protection Authority (). All information regarding human material was managed using anonymous numerical codes, and all samples were handled in compliance with the Helsinki Declaration ().